articles about PCV2 in Press releases

TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds.

Since 2007, Boehringer Ingelheim Animal Health has funded independent European research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. So far, 17 research projects have been awarded, each supported with 25,000 euro, in total 425,000 euro.

Veterinarians and farmers across the globe have reached the landmark of protecting one billion pigs from the potentially devastating effects of Porcine Circovirus Disease (PCVD) using Ingelvac CircoFLEX®

Fostera™ PCV is the only PCV vaccine that can be incorporated into vaccination programs using either two doses or one to help prevent Porcine Circovirus Type 2 (PCV2) viremia and help control lymphoid depletion.

For the fifth time, the European PCV2 Research Award sponsored by Boehringer Ingelheim funds research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Nine high quality research proposals were submitted from seven different countries (UK, Italy, Spain, Sweden, Denmark, Estonia, and France).

Mycoplasmal pneumonia and porcine circovirus are two of the costliest diseases affecting pork producers. Helping provide protection before disease exposure is critical to the success of any vaccination program.

Veterinarians and pork producers can now help prevent Porcine Circovirus Type 2 (PCV2) viremia with the convenience of a single dose. New Fostera™ PCV from Pfizer Animal Health is the result of the company's commitment to best practices and continuous quality improvements.

An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases. In 2011, this meeting heard, it is 15 years since the name PMWS was first proposed by Canadian investigators Ted Clark and John Harding for the novel wasting disease of growing pigs that they were observing in herds in Western Canada

Intervet/Schering-Plough Animal Health has introduced BacuCheck™, a simple ELISA test for confirmation of vaccination status with PORCILIS® PCV of piglets against porcine circovirus type 2. The announcement was made today during a dedicated symposium at the 6th International Symposium on Emerging and Re-emerging Pig Diseases that currently takes place in Barcelona (Spain).

Intervet/Schering-Plough Animal Health announces today that a field trial with the single-dose subunit vaccine PORCILIS® PCV has confirmed that vaccination induces humoral and cellular immunity and protects piglets against the consequences of porcine circovirus-associated disease (PCVD).

The fourth edition of the European PCV2 Research Award sponsored by Boehringer Ingelheim saw a record number of applications showing the continued interest in Porcine Circovirus Type 2 (PCV2) research: 13 researchers from ten different countries submitted proposals.

On November 29th 2010, CIRCOVAC was granted a European marketing authorization for use in piglets. CIRCOVAC is now the first PCVD vaccine available worldwide for the vaccination of both sows and piglets; it is registered in Europe, Brazil, Mexico and Thailand.

Simultaneous (mixed) use of existing swine vaccines against porcine circovirus 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) from Intervet/Schering-Plough Animal Health in swine are as efficacious and safe as separate use of these vaccines.

The EU Commission has approved the simultaneous use of the pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® in the European Union. Boehringer Ingelheim will market this unique vaccine concept under the name FLEXcombo®.